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B cell development starts in bone marrow with the commitment of hematopoietic progenitors to the B cell lineage. In murine
models, the IL-7 and preBCR receptors, and the signaling pathways and transcription factors that they regulate, control
commitmentandmaintenancealongtheBcell pathway.E2A,EBF1,PAX5,andIkarosareamongthemostimportanttranscription
factors controlling early development and thereby conditioningmice homeostaticB cell lymphopoiesis.Importantly, their gain or
loss of function often results in malignant development in humans, supporting conserved roles for these transcription factors. B
cell acute lymphoblastic leukemia is the most common cause of pediatric cancer, and it is characterized by unpaired early B cell
development resulting from genetic lesions in these critical signaling pathways and transcription factors. Fine mapping of these
genetic abnormalitiesis allowing more speciﬁc treatments, more accurately predicting risk proﬁles for this disease, and improving
survival rates.
1.Introduction
The main function of mature immunocompetent B cells
is to make antibodies; therefore, they are responsible for
the adaptive humoral immune response. Formation of these
mature B cells is a highly ordered multistep process that in
adult mammals starts in bone marrow with the commitment
of hematopoietic stem cells to the B cell lineage and ends
with formation of mature B cells in secondary lymphoid
organs. This developmental process was once thought to
be inﬂexible, unidirectional, and irreversible, but recent
lines of evidence support a higher level of plasticity to the
diﬀerentiating cell. Several transcription factors (TFs) play
critical roles in commitment and maintenance along the
Bc e l lp a t h w a y ,a n dt h e i rg a i no rl o s sa ﬀects homeostatic
B cell lymphopoiesis and often results in malignant trans-
formation.
2.The EarlyStagesofB CellDevelopment
B cells express receptors (BCRs) to various antigens; each
BCR is uniquely specialized to recognize and counteract a
particular new or recurrent pathogen. The main goal of B
cell development is to generate B cells expressing a diverse
repertoire of BCRs. This receptor is a membrane-bound
immunoglobulin(Ig)consistingofaheterodimerofidentical
pairs of the Ig heavy and light chains, which are responsible
for the clonal diversity of the B cell repertoire. The Ig heavy
and light chain heterodimer is, however, unable to generate
signals to trigger biological responses after antigen binding;
this function is mediated by the disulﬁde-coupled het-
erodimer of Igα (CD79a) and Igβ (CD79b), which is
noncovalentlyassociatedwith theIgantigenrecognitionunit
[1]. It is the sequential expression and assembly of these
BCRcomponentsthatdeﬁneseachdevelopmentalstage,and,
therefore, each stage is characterized by a particular form2 Bone Marrow Research
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Figure1:Bcell developmentinadult mammalsstartsinbonemarrowwiththecommitmentofhematopoieticstemcells (HSCs)totheBcell
lineage and ends with formationof mature B cells in peripheral secondary lymphoid organs (e.g., the spleen). It is the sequential expression
and assembly of the components of the B cell antigen receptor (BCR) what deﬁnes each developmental stage. The ﬁrst stage exhibiting
commitmentto theB cell lineageistheproB, andhere the immunoglobulinheavychain isin theprocess ofrecombination,andthe signaling
proteins Igα andIgβ are insurface formingcomplexes withchaperon proteins likecalnexin(theproBCR). The next developmentalstage,the
preB, happens after the heavy chain was successfully recombined and the preBCR is assembled. In this stage, the light chain is recombined
and unrearranged heavy chain alleles are excluded. After light chain recombination and pairing with the heavy chain and Igα and Igβ the
mature BCR is formed, the B cell is in the immature (in bone marrow) and transitional (in periphery) stages. Here, B cell mechanisms of
self-tolerance are active allowingself- and nonself-recognition by the mature B cell. Transition to the mature stage happens if the BCR of the
immature/transitional B cell does not ﬁnd its cognate antigen after several days of bone marrow and peripheral traﬃcking.
of the BCR, reﬂecting the progression of receptor assembly
(Figure 1)[ 2, 3].
To achieve BCR clonal diversity, the Ig heavy and light
chain genes are composed of constant and variable regions.
The variable region is formed by a series of segments termed
V (variable), D (diversity), and J (joining) (Figure 2(a)),
which are brought together by a site-speciﬁc recombination
process termed VDJ recombination. This is a highly ordered
process during which the D and J fragments are rearranged
and the V segment is then joined to the DJ fragment; these
steps occur ﬁrst in the heavy and then in the light chain loci
(Figure 2(b))[ 4, 5]. This process is essential for the lympho-
cyte’s adaptive immune function. The ﬁrst developmental
stage exhibiting commitment to the B cell lineage is called
proB and is characterized by rearrangement of the Ig heavy
chain [2]. The proB stage is further divided according to the
status of the heavy chain; in mice, Marshall named these
substages proB-A (during which the heavy chain is in the
germ line state), B (during which D and J are recombined),
and C (during which V-DJ is recombined) [6]. These stages
are better known in humans as early proB or preproB (A),
proB (B) and preB I (C) (Figure 2(b)).
In the proB stage Igα and Igβ are expressed at the
c e l ls u r f a c ei na s s o c i a t i o nw i t hc h a p e r o np r o t e i n ss u c ha s
calnexin [7]. As soon as the heavy chain is successfully
recombined, it is assembled with Igα and Igβ and the
surrogate light chains λ5a n dV p r e Bt of o r mt h ep r e B C R .
Surfaceexpressionofthisreceptormarksthetransitiontothe
preB stage (Figure 1)[ 5]. Unsuccessful recombination (with
heavy chain VDJ fragments that are not in a proper reading
frame) or unsuccessful pairing of the preBCR components
results in proB cells that are unable to proceed to the preB
stage and leads to apoptosis. This observation supports
an active signaling role for the preBCR in generating the
permissive signal thatallows diﬀerentiationthroughthepreB
stage. In the preB stage, the light chain V and J fragments are
recombined, and, again, successful assembly of the mature
form of the BCR marks the transition to the immature stage
(Figures 1 and 2(b))[ 2, 4, 8, 9].
In addition to their VDJ recombination status, all proB
and preBstages canberecognized bytheirpatterns ofsurfaceBone Marrow Research 3
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Figure 2: (a) The Ig heavy and light chain genes are comprised of constantand variable regions, where the variable region is formed by an n
number of segments termed V (variable), D (diversity), and J (joining) in the heavy chain and by segments V and J in the light chain. These
segmentsarebrought together bya site-speciﬁc recombinationprocesstermed VDJ recombinationresponsiblefortheextensive repertoire of
BCR speciﬁcities. There are two loci for lightchain,κ andλ. Here, all the loci are shownin germlineconﬁguration,previous to the process of
VDJ recombination. (b) The early stages of B cell development are diﬀerentiated by the process of VDJ recombination, and the heavy (IgH)
and light (IgL) chains are recombined in the proB and preB stages, respectively. Each stage is further subdivided according to the sequential
assembly of the VDJ segments. Replication and recombination processes are mutually exclusive as denoted by the circular arrows and VDJ
signsinsidethecell. DashedlinesseparatingproBandpreB stagesindicatecheckpointswhere signalingfromthepreBCR andBCRisrequired
for positive selection and progression along the B cell maturation pathway. Continuous lines indicate the main receptors controlling each
developmental stage. The diﬀerential intensity in the IL-7 green line indicates the sub-stages where a higher or lower concentration of the
IL-7R ligand is required.
markers expression and their proliferative state [6]. Because
DNA replication during proliferation is associated with
homologous recombination and VDJ rearrangement is as-
sociated with nonhomologous recombination, these two
processes are mutually exclusive. ProB and preB stages are
thus characterized by waves of VDJ recombination followed
by waves of proliferation [6, 10]. To achieve this pattern, the
expression of the two main enzymes responsible for VDJ
rearrangement, the recombinase associated genes 1 and 2
(RAG1 and RAG2), are tightly regulated during the cell
cycle; they are highly active in G0 and degraded before
entrance into S phase [11–13]. The developing B cell thereby
ensures that no events of non-homologous recombination
will occur during DNA replication and avoids an increase
in the mutation rate. This ﬁne regulatory control separating
proliferation and diﬀerentiation could explain why the
proliferative proB and preB substages are often found to be
compromised in B cell acute lymphoblastic leukemia (ALL)
and why leukemic cells are often unable to diﬀerentiate. In
proB, proliferative stages occur in early proB or preproB
(before heavy chain recombination) and preB-I (after heavy
chain recombination), whereas in preB proliferation occurs
during the large preB-II stage (before light chain rearrange-
ment) (Figure 2(b))[ 6, 10].
3.RegulationofLineageCommitment:The
CriticalRoleof IL-7R,PreBCR,and
DownstreamBcell TranscriptionFactors
Limitation oflineage choice during developmentis regulated
by a combination of signaling pathways and transcription
factors(TFs).Inmice,themainreceptorcontrollingtheproB
s t a g ei st h eI L - 7 R ,w h i c hi sc o m p o s e do fa nα chain (IL-7Rα)
and the common cytokine receptor γ chain (γc) [14, 15].
Deletion of IL-7Rα or γc leads to developmental arrest at
the early proB stage [16–19]. Loss of IL-7 also aﬀects T cell
development; however, this can be overcome by enforced
expression of Bcl2, supporting a key role in proT and preT
survival [20, 21]. On the other hand, enforced expression
of antiapoptotic genes cannot compensate for IL-7R loss in
B cell development, indicating additional roles for IL-7 in
this lineage [22]. In humans, B cells can still be generated
in severe combined immunodeﬁciency (SCID) patients with
mutations in the IL-7R gene, suggesting that IL-7 signaling is4 Bone Marrow Research
notasessential forhuman Bcelldevelopment[23].However,
a recent study has demonstrated that in vitro human B cell
production is IL-7 dependent [24].
IL-7 activates three major signaling pathways: (1) JAK-
STAT, (2) phosphatidylinositol 3-kinase (PI3K)-Akt, and (3)
Ras-Raf-Erk [25]. STAT5 (signal transducer and activator of
transcription 5) is the predominant STAT protein activated
by IL-7 [25, 26]. STAT5 is a transcription factor that consists
of two highly related isoforms, STAT5A and STAT5B; these
proteins play redundant roles because the loss of only
STAT5A or STAT5B has minor consequencesfor lymphocyte
function [26]. However, when both STAT5s are lost, B cell
development is arrested at the early proB stage, indicating
that STAT5 is an essential mediator of IL-7 signaling in
early B cell development [27, 28]. IL-7/STAT5 signaling also
promotescell survival via theactivation oftheanti-apoptotic
gene Mc1 [29]. Once the preBCR is expressed, it can take
over many of the functions performed by the IL-7 receptor.
The preBCR can signal constitutively or when activated by
binding to nonpolymorphic ligands; like IL-7R, it activates
the PI3K-Akt and Ras-Raf-Erk pathways [8, 30]. It has been
shown that proliferation of large preB-II cells is dependent
on the preBCR acting in concert with low (picogram) levels
of IL-7 (Figure 2(b))[ 31]. The CCND3 gene, which encodes
for cyclin D3, is essential for pre-B cell expansion and
integrates IL-7R and preBCR signals [32].
Downstream oftheIL-7andpreBCRreceptors,ahandful
of TFs have been observed to be critical for commit-
ment to the B cell lineage and early development; these
include E2A/TCF3 (immunoglobulin enhancer binding fac-
tors E12/E47/transcription factor 3), EBF1 (Early B cell
Factor 1), and PAX5 (Paired box 5) [33–35]. Loss of E2A
and EBF1 blocks entry into the B cell lineage, and loss of
PAX5 redirects B cells into other lineages [35–37]. Thus,
there is a hierarchical relationship in the expression of these
transcription factors, with some genes regulating entry into
the B cell lineage and others regulating commitment to this
lineage [36, 38–40]. Ig recombination generally correlates
with germline transcription; transcription probably allows
changes inthechromatin structureand/orRAGsaccessibility
[5]. One of the main molecular functions of PAX5 (acting
together with E2A, EBF1 and STAT5) is to allow VDJ
recombination[41–43].EctopicexpressionofPAX5andE2A
allows VDJ recombination in non-B cells [44, 45]. Also, E2A,
PAX5,IKZF1,andRUNX1,amongotherTFs,are responsible
for RAG expression [46, 47]. Therefore, IL-7R signaling
fulﬁlls an essential role in early B cell development, with
STAT5 participating in the activation of the B cell regulatory
genes E2A, EBF1, and PAX5 [37].
E2A encodes two TFs via alternative splicing, E12 and
E47. In mice lacking the E2A gene, the B cell lineage is lost,
there is no heavy chain recombination, and the expression
of the B-cell-restricted genes EBF1, PAX5, CD79A/B, IGLL1,
and VPREB1 (CD179A)i sa l s oa ﬀected [48, 49]. The absence
of the E47 isoform results in a diminished B cell popula-
tion, suggesting a signiﬁcant role for E47 homodimers in
diﬀerentiation. In contrast, the lack of E12 results in normal
but ineﬃcient B cell diﬀerentiation [50]. Loss of EBF1
results in B cell arrest before heavy chain recombination
and failure to express the preBCR components Igα and Igβ
and the surrogate light chains λ5a n dV P R E B[ 51]. Enforced
expression of EBF1 and PAX5 is suﬃcient to overcome the
developmental block in mice deﬁcient in E2A, IL-7, or IL-
7Rα, further illustrating the transcriptional hierarchy of the
B-cell speciﬁc program triggered by IL-7 receptor signaling
[37, 52–56].
The EBF1 promoter is responsive to PAX5, ETS1, and
SP11 (PU.1) and together with PAX5 drives the expression
of many genes critical for early B cell development and
B cell function, including FOXO1, MYCN, LEF1, BLNK,
CD79A (MB-1), RAG2, CD19, and CR2 (CD21)[ 37, 51, 57].
EBF1also works atan epigeneticlevel,controlling chromatin
structure by recruitment of molecules as RUNX1 and E-
proteins [40, 58]. EBF1 expression has been implicated
in demethylation of the CD79A promoter, and together
with PAX5 and other transcriptional activators, it generates
genomic regions of active chromatin [59]. PAX5 can be a
positive or negative regulator depending on the transcrip-
tional context [60]; it is generally a positive regulator of
B-cell-speciﬁc genes such as EBF1, CD19, MB-1, BLNK,
IGLL5, and VPREB1 [34, 61] and a repressor of non B-
lineage genes such as M-CSR, NOTCH1, and FLT3 [62–
64]. Genome-wide transcriptional analysis has identiﬁed a
plethora of genes targeted by both EBF1 and PAX5, which
cooperate to activate the B cell gene expression program and
to allow lineage maintenance by inhibiting the expression
of genes associated with other developmental programs and
hematopoietic progenitors [65, 66]. Because of EBF1 and
PAX5-mediated transcription of B-cell-speciﬁc genes and
repression of genes associated with other lineages, B cell
development is unidirectional and perhaps irreversible in
homeostatic conditions [34, 36, 59, 63, 67, 68].
Also important for lymphoid development are members
of the Ikaros family of TFs, mainly IKZF1 (which encodes
Ikaros) and IKZF3 (which encodes Aiolos); both TFs bind
to the same consensus sequence as either homodimers
or heterodimers playing distinct roles in B and T cell
diﬀerentiation [69, 70]. Ikaros activates CD19 and represses
genes that are unrelated to the B lineage, such as CD4 [71].
Expression of IKZF1 and IKZF3 is regulated by alternative
splicing,which produceslongisoforms(Ik-1,Ik-2,Ik-3,Aio-
1,Aio-3,Aio-4,andAio-6)thathaveatleastthreezincﬁngers
andeﬃcientlybindtoDNA,andshort isoforms(Ik-4,Ik-5/7,
Ik-6, Ik-8, Aio-2, Aio-5) that have less than two zinc ﬁnger
domains, are unable to bind DNA with high aﬃnity, and
do not activate transcription; these short forms, therefore,
act as dominant negatives [69, 72, 73]. Ikaros is activated
in early stages of lymphopoiesis and is required for both
early and late events in lymphocyte diﬀerentiation. Ikaros
and Helios (another member of the Ikaros family; IKZF2)
have opposite regulatory roles of the expression of INPP5D
gene encoding the SHIP phosphatase, a BCR signaling
negative regulator [74]. Aiolos is not required during the
early speciﬁcation of the B and T lineages but is essential
during B cell maturation [75]. Aiolos together with Ikaros
act in concert to repress c-Myc expression in large preB
cells with concomitant repression and induction of genes
CCND3 and CDKNIB, respectively [76], thus promotingBone Marrow Research 5
preB cell cycle exit and transition to small preBs where
light chain recombination occurs. Therefore, Aiolos has a
role during B cell commitment and together with Ikaros
during B cell maintenance, hence, mice lacking Ikaros lack
all lymphoid lineages [77, 78], whereas Aiolos-deﬁcient mice
have an increased pre-B cell population and develop B cell
lymphomas [75].
4.Genetic Abnormalities in Human Pediatric B
CellAcuteLymphoblasticLeukemia
Because all these TFs are critical for early murine B cell
development, it is not surprising that abnormalities in these
genes have often been found in human B cell acute lym-
phoblastic leukemia (B-ALL). ALL is the most common
childhood cancer and is characterized by impaired early
lymphoid development. ALL can be classiﬁed as B or T cell
ALL; B-ALL is the one most frequently found (83% of ALLs
and 30% to 40% of all childhood cancers) [79, 80]. A high
percentageofBcell ALLpatientshavegeneticlesions(mostly
chromosomal translocations) that are speciﬁcally associated
with the leukemic cells. In recent years, eﬀorts have focused
on the identiﬁcation of the speciﬁc developmental stage
where the ALL cells are arrested and the genetic lesions
responsible for the leukemia phenotype. These data have
helped to classify the disease, stratify the patients into risk
groups and design speciﬁc therapies that have signiﬁcantly
improved the survival rate [65, 66].
RUNX1 (Runt-related transcription factor 1) is a fre-
quent target for chromosomal rearrangements and muta-
tions in ALL. RUNX1 (AML1 or CBFα2) encodes a TF that
possesses a Runt domain, which is essential for interaction
with CBFβ, a heterodimer that regulates transcription of
genes that are important in hematopoiesis. CBF cooperates
to regulate the survival of early pro-B cells and establish a B-
lineage-speciﬁc transcriptional program [81]. A substantial
proportion (25% of children and 2% of adults) of ALL
patients present the ETV6/RUNX1 fusion as a result of the
translocation t(12;21)(p12;q21). In contrast to the normal
function of this TF, the chimeric protein recruits corepres-
sors and histone deacetylases to create stable repression
complexes at the promoters of RUNX1 target genes [82].
Homozygous mutations in RUNX1 in mice are lethal, with
embryoslackingfetalliverhematopoiesis[83,84].Thisresult
supports the idea of diﬀerent roles for this TF in mice and
humans and suggests that RUNX1 plays a more profound
role at an earlier stage of murine hematopoiesis.
The TF E2A has been found in various chromo-
somal translocations; among the most common are
t(1;19)(q23;p13),which results in the E2A-PBX1 fusion, and
t(17;19)(q22;p13), resulting in E2A-HLF (hepatic leukemia
factor). These abnormalities are detected in 5-6% and 1% of
children ALL, respectively, and are found in less than 5% of
adultcases[37, 85].These fusionproductspossess properties
that the original proteins do not have. E2A-PBX1 consists of
the E2AN-terminal TF domain fused to the Hox cooperative
motif and homeodomain of C-terminal PBX1. PBX1 mod-
ulates the DNA binding activity of speciﬁc subsets of Hox
proteins, which participate in normal hematopoiesis, and
the chimeric protein E2A-PBX1 may disturb Hox activity
[37, 85]. E2A-PBX1 is considered a potent transcriptional
activator of the WNT16 gene; because the WNT family is
widely known to be involved in oncogenesis, impairment of
WNT signaling could be a mechanism of leukemia initiation
[86]. E2A-HLF encodes a chimeric protein that contains the
E2A N-terminal fused to the C-terminal basic leucine zipper
ofHLF.E2A-PBX1andE2A-HLFfusionproteinsdonotbind
the same DNA motifs and might regulate diﬀerent sets of
genes, disturbing diﬀerent processes. E2A-HLF promotes the
enhanced survival of early B cells activating expression of the
anti-apoptotic TFs SNAI2 (SLUG) and LMO2, accordingly,
gene silencing of LMO2 in an E2A-HLFpos cell line-induced
apoptotic cell death [87].
The MLL (mixed lineage leukemia) gene is often rear-
ranged in patients with ALL, both de novo and therapy-
related. Leukemias with MLL translocations can be myeloid
or lymphoid and often tend to express both lineage markers,
probably indicating a very early multipotent progenitor
origin [88, 89]. Today, more than 50 fusions involving MLL
have been documented. The translocation t(4;11)(q21;q23)
that fuses the MLL and AF4 g e n e si sp r e s e n ti nt h em a j o r i t y
of the de novo cases and represents up to 80% of the
infant, 2% of children older than 1-year old, and 5 to
10% of adult ALLs. MLL possesses a Trithorax domain that
participates in the methylation of lysine 4 of histone H3
(H3K4), and this function is associated with transcriptional
activationoftargetpromoters;importantforleukemogenesis
are HOX genes and Meis1.H o xp r o t e i n sa r eah i g h l y
conserved homeobox containing family of TFs that regulates
cell fate, including hematopoietic lineage decisions [88–90].
Recent data show that MLL and MLL-fusion proteins are
recruitedtothetargetgenesbythetranscriptional elongation
factor Paf1c, and this interaction is required to increase
the expression of HOX genes and transformation of bone
marrow cells [90].
Another important translocation is t(9;22)(q34;q11)
(also known as Philadelphia chromosome), which fuses the
genes BCR and ABL1 and is found in 5% of childhood and
25% of adult B cell ALL. Unregulated expression of STAT5
has been observed to be associated with BCR-ABL1 [91, 92].
STAT5inactivation resultsincellcyclearrestandapoptosisof
BCR-ABL1pos malignant B cells, and BCR–ABL1 expression
isunable toinduce leukemiain STAT5-/- mice, supporting an
important role for STAT5 in the initiation of BCR-ABL1pos
transformation. Genome-wide analysis of B cell ALL has
identiﬁed mutations in the Janus kinases (JAK1 and JAK2)
in up to 10% of patients [92]. Interestingly, patients with
JAK1/2 mutations and patients with the BCR-ABL1 fusion
both have a similar gene expression proﬁle and a high-
risk prognosis [91]. JAK1 and 2 are activated after IL-7R
engagement and mediate STAT5 activation; most mutations
in these proteins occur in the kinase domain, constitutively
activating the JAK-STAT signaling pathway. JAK gain-of-
function mutations are insuﬃcient to confer a transformed
phenotype, and it has been demonstrated that 100% of B-
ALL cases with JAK2 mutations overexpress CRLF2 (type
I cytokine receptor subunit, also known as thymic stromal
lymphopoietin receptor) [66]. CRFL2 forms a heterodimeric6 Bone Marrow Research
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Figure 3: Homeostatic and leukemic expression of receptors,
signaling proteins, and transcription factors along the B cell
pathway. Developmental stages are indicated starting with the
hematopoietic stem cell (HSC), the common lymphoid progenitor
(CLP), and into the B cell pathway, stages proB, preB, and mature
B cells. Normal gene expression along the developmental pathway
is indicated with blue bars, and expression dependency between
proteins is indicated with arrows. Most common modiﬁed forms
of these receptors, signaling proteins, and transcription factors
associated with acute lymphoblastic leukemia are also indicated.
complex with the IL-7R and is overexpressed in 15% of B-
ALL cases as a result of translocations or intrachromosomal
deletions [66, 92]. In a subset of cases, CRLF2 acquires a
Phe232Cys gain-of-function mutation that promotes consti-
tutive dimerization and cytokine-independent proliferation
[92]. In agreement with data suggesting an association
between CRLF2 and the JAK-STAT signaling pathway in B-
A L L ,t h eg e n ep r o ﬁ l ea s s o c i a t e dw i t hC R L F 2o v e r - e x p r e s s i o n
is also highly similar to that found in BCR-ABL1pos B-
ALL. In a subgroup of aggressive treatment-resistant B ALL,
deregulation of the JAK-STAT pathway is associated with
abnormalities in genes such as IKZF1 and CDKN2A/B [66,
91, 92].
Genome-wide analysis has also identiﬁed abnormalities
in PAX5 and EBF1 in B ALL [93]. In the case of PAX5,
these abnormalities are generally (a) point mutationslocated
i ne x o n s2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,a n d1 0 ,m o s to fw h i c ha r e
clustered within functional domains or (b) alterations in
the expression of splice variants of PAX5 [94, 95]. These
alterations have been found in up to 32% of children and
30% of adults with B ALL and in 35% of relapsed cases
[93, 96, 97]. Almost 35% of patients with PAX5 lesions lack
expression of the full-length protein and express only short
variants [95]. Mullighan et al. reported PAX5 deletions in
51% ofBCR-ABL1pos BA L Lc a s e s[ 91].However, the speciﬁc
association between aberrant splicing and PAX5 mutations
with speciﬁc genetic subtypes of B ALL is controversial [95].
In addition, PAX5 (9p11) participates in gene fusions. Cur-
rently, ﬁve PAX5 fusions have been identiﬁed, with the gene
partners LOC392027 (7p12.1), SLCO1B3 (12p12), ASXL1
(20q11.1), KIF3B (20q11.21), and C20orf112 (20q11.1). All
of the resulting chimeric proteins retain the paired domain
of the TF, and, as for the previously described deletions,
the gene fusions result in lowered expression of PAX5 and
its target genes [98]. EBF1 alterations are also common in
patients with poor outcomes. In a cohort of 45 adolescent
andadultALLcases,deletionsinEBF1wereobservedin4.4%
of cases; in relapsed children, EBF1 deletions are particularly
frequent (25%),suggesting a possible contributionof this TF
for the development of relapse and a potential prognostic
value [65, 66, 97, 99].
High expression levels of the short Ikaros isoforms,
particularly the dominant negative Ik-6, are also associated
with high risk leukemia [100–105]. However, recent reports
haveshowed thatall Ikaros isoforms areexpressed in patients
with B ALL, although their level of expression diﬀers [106].
Most of the BCR-ABL1pos B ALL patients have deletions in
IKZF1 and increased levels of the short isoforms; however,
Ik-6 has also been found to be elevated in BCR-ABL1neg
patients. In all these cases, deletion in the IKZF1 gene is
associated with a poor outcome; therefore, Ikaros isoform
expression isanimportantprognosticfactorinBCR-ABL1pos
andBCR-ABL1neg BALL[91,107].ElevatedexpressionofIk-
6 is frequently correlated with elevated expression of Aiol-
1[ 105]. It has been proposed that the high level of Ikaros
shortisoformexpressionisduetogeneticlesions.Supporting
this idea, IKZF1 somatic deletions have been found in up to
35% of recurrences [97] and in 23.9% of the patients with
elevated levels of minimal residual disease [107]. Thereby,
full-length Ikaros seems to be a leukemia suppressor that
is inhibited by its dominant negative isoforms [101]. The
currently available information on IKZF3 expression in ALL
is limited. However, Liippo et al. reported that the majority
of the patients with ALL expressed several Aiolos isoforms
[72]. A summary of homeostatic and leukemic expression of
receptors, signaling proteins, and transcription factors along
the B cell pathway is shown in Figure 3.
5.Conclusion
Genes critical for commitment to the B cell lineage and
B cell maintenance are often mutated in B ALL. Genome-
wide analysis methods that measure expression levels and
assess the presence of genetic and epigenetic abnormalities
in B cell ALL have recently provided new insights into the
genetic lesions most frequently associated with this disease.
These genetic signatures are paving the way for (1) a better
understanding of the origin of B cell ALL, (2) a precise
classiﬁcation of the disease, and (3) accurate predictive
proﬁles, which are especially necessary forthose patientsthat
lack a high-risk associated translocation but are prone to
relapse. These data will also be useful for the generation of
more eﬀective drugs that act speciﬁcally to complement or
counteract the genetic lesions associated with ALL. In the
near future, such drugs will have a major impact on the
overall cure rates [65, 66].
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